Industry
Biotechnology
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Insights
June 19, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Insights
June 18, 2024 | 12:07 pm
Portfolio Pulse from Benzinga Insights
June 17, 2024 | 8:31 pm
Portfolio Pulse from Benzinga Newsdesk
April 09, 2024 | 1:34 pm
Portfolio Pulse from Benzinga Insights
February 27, 2024 | 5:31 pm
Portfolio Pulse from Avi Kapoor
January 11, 2024 | 12:51 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 1:33 pm
Portfolio Pulse from Benzinga Insights
October 30, 2023 | 5:30 pm
Portfolio Pulse from Benzinga Insights
October 30, 2023 | 1:05 pm
Portfolio Pulse from Happy Mohamed
August 17, 2023 | 12:33 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.